设为首页 电子邮箱 联系我们

本刊最新招聘信息请见“通知公告”!  本刊投稿系统试运行中,欢迎投稿!如投稿有问题,可直接将稿件发送至zgyy8888@163.com

 

主管单位:中华人民共和国   

国家卫生健康委员会

主办单位:中国医师协会
总编辑:
杨秋

编辑部主任:吴翔宇

邮发代号:80-528
定价:28.00元
全年:336.00元
Email:zgyy8888@163.com
电话(传真):010-64428528;
010-64456116(总编室)

                  

过刊目录

2022 年第 3 期 第 17 卷

血浆纤维蛋白原水平与非瓣膜性心房颤动患者左心耳血栓形成的关系

The relationship between plasma fibrinogen level and left atrial appendage thrombosis in patients with nonvalvular atrial fibrillation

作者:马林张春秀拜文廉

英文作者:Ma Lin Zhang Chunxiu Bai Wenlian

单位:甘肃省临夏回族自治州人民医院心血管内科,临夏731100

英文单位:Department of Cardiovascular Medicine People′s Hospital of Linxia Hui Autonomous Prefecture Gansu Province Linxia 731100 China

关键词:非瓣膜性心房颤动;纤维蛋白原;左心耳血栓;相关性

英文关键词:Nonvalvularatrialfibrillation;Fibrinogen;Leftatrialappendagethrombosis;Correlation

  • 摘要:
  • 目的 探讨非瓣膜性心房颤动(NVAF)患者血浆纤维蛋白原(FIB)水平与左心耳血栓形成(LAAT)的相关性。方法  选取201912月至202011月于甘肃省临夏回族自治州人民医院住院治疗的NVAF患者212例为研究对象。收集患者临床资料,根据患者是否产生LAAT将患者分为形成组(70例)和非形成组(142例),比较2组临床资料。Logistic回归法分析NVAF患者发生LAAT的危险因素,采用Spearman相关性分析方法分析NVAF患者血浆FIB水平与发生LAAT的相关性。依据FIB水平三分位数将患者分为低FIB组(≤2 g/L)、中FIB组(>2<4 g/L)和高FIB组(≥4 g/L),Cox回归模型分析NVAF患者FIB水平与LAAT风险的关系,依据NVAF患者发生LAAT的独立危险因素构建预测模型,评价预测效能。结果 年龄>67岁、心房颤动病程>36个月、左心房前后径>37.20 mmB型脑钠肽>311.65 ng/LFIB>2.98 g/L、血尿酸>438 μmol/LCHA2DS2-VASc评分>5分、冠心病(冠状动脉粥样硬化性心脏病)、心力衰竭是NVAF患者发生LAAT的独立危险因素(均P<0.05)。FIB水平与LAAT呈正相关(r=0.691, P=0.001)。低FIB组患者发生LAAT的风险显著低于高FIB组(风险比=2.85295%置信区间1.3026.432P=0.005)。基于LAAT的独立危险因素构建LAAT预测模型,该模型在训练集(159例)中曲线下面积为0.77195%置信区间:0.6200.966),在测试集(53例)中曲线下面积为0.75695%置信区间:0.6610.995),其间差异无统计学意义(P=0.142)。结论  FIB水平是NVAF患者发生LAAT的独立危险因素,临床应及时关注并纠正NVAF患者FIB水平。

  • Objective   To explore the relationship between plasma fibrinogen (FIB) level and left atrial appendage thrombosis(LAAT) in patients with nonvalvular atrial fibrillation(NVAF). Methods   From December 2019 to November 2020, 212 inpatients with NVAF admitted to Peoples Hospital of Linxia Hui Autonomous Prefecture, Gansu Province were selected. The clinical data of patients were collected, patients were divided into forming groups(70 cases) and non-forming groups(142 cases) according to whether they had LAAT, and clinical data were compared between the two groups. Logistic regression method was used to analyze the risk factors of LAAT in patients with NVAF, and Spearman correlation analysis was used to analyze the relationship between FIB and LAAT in patients with NVAF. Patients were divided into low FIB group(2 g/L), moderate FIB group(>2-<4 g/L) and high FIB group(4 g/L) according to the tertiles of plasma FIB level. Cox regression model was used to analyze the relationship between the FIB level and the risk of LAAT in patients with NVAF. The predictive model was constructed based on the independent risk factors of LAAT in NVAF patients, and its predictive effectiveness was evaluated. Results  Age>67 years, atrial fibrillation course>36 months, left atrial anteroposterior diameter>37.20 mm, brain natriuretic peptide>311.65 ng/L, FIB>2.98 g/L, serum uric acid>438 μmol/L, CHA2DS2-VASc score>5, coronary atherosclerotic heart disease and heart failure were independent risk factors for LAAT in patients with NVAF(all P<0.05). FIB level was positively correlated with LAAT (r=0.691, P=0.001). The risk of LAAT in patients of low FIB group was significantly lower than that of high FIB group(hazard ratio=2.852, 95% confidence interval: 1.302-6.432, P=0.005). The LAAT predictiive model was constructed based on the independent risk factors of LAAT. The area under the curve(AUC) of the model in training set (159 cases) was 0.771(95% confidence interval: 0.620-0.966). The AUC of the LAAT predictive model for NVAF patients in test set was 0.756(95% confidence interval: 0.661-0.995). Compared with the training set, the difference in AUC was not statistically significant(P=0.142). Conclusion High FIB level is an independent risk factor for LAAT in patients with NVAF. Clinicians should pay attention to and correct the FIB level in patients with NVAF in time.

copyright 《中国医药》杂志编辑部
地址:北京市朝阳区安贞路2号首都医科大学附属北京安贞医院北楼二层
电话:010-64456116 传真:010-64428528 邮编:100029 Email: zgyy8888@163.com
网址:www.chinamedicinej.com 京ICP备2020043099号-3

当您在使用本网站投稿遇到困难时,请直接将稿件投送到编辑部邮箱zgyy8888@163.com。







安卓


苹果

关闭